Pharmacogenetic Determinants of Mercaptopurine Disposition in Children with Acute Lymphoblastic Leukemia

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2012 Mar 17

PMID 22421815

Citations 23

Authors

Tiphaine Adam de Beaumais

Evelyne Jacqz-Aigrain

Affiliations

Soon will be listed here.

Abstract

Background: The backbone of drug therapy used in acute lymphoblastic leukemia (ALL) in children includes 6-mercaptopurine (6-MP). Intracellular metabolism of this prodrug is a key component of the therapeutic response. Many metabolizing enzymes are involved in 6-MP disposition and active 6-MP metabolites are represented by 6-thioguanine nucleotides (6-TGN) and methylated metabolites primarily methylated by the thiopurine S-methyltransferase enzyme (TPMT). The genetic polymorphism affecting TPMT activity displays an important inter-subject variability in metabolites pharmacokinetics and influences the balance between 6-MP efficacy and toxicity: patients with high 6-TGN levels are at risk of myelosuppression while patients with high levels of methylated derivates are at hepatotoxic risk. However, the genetic TPMT polymorphism does not explain all 6-MP adverse events and some severe toxicities leading to life-threatening conditions remain unexplained. Additional single nucleotide polymorphisms (SNPs) in genes encoding enzymes involved in 6-MP metabolism and 6-MP transporters may also be responsible for this inter-individual 6-MP response variability.

Aim: This review presents the pharmacogenetic aspects of 6-MP metabolism in great detail. We have focused on published data on ALL treatment supporting the great potential of 6-MP pharmacogenetics to improve efficacy, tolerance, and event-free survival rates in children with ALL.

Citing Articles

Pharmacogenomics of Chemotherapies for Childhood Cancers in Africa: A Scoping Review.

Katabalo D, Mwita S, Liwa A, Kidenya B, Schroeder K Pharmgenomics Pers Med. 2025; 18:55-69.

PMID: 39968370 PMC: 11834739. DOI: 10.2147/PGPM.S502355.

Pharmacogenomics in Children.

Rieder M, Elzagallaai A Methods Mol Biol. 2022; 2547:569-593.

PMID: 36068477 DOI: 10.1007/978-1-0716-2573-6_20.

Effect of ITPA Polymorphism on Adverse Drug Reactions of 6-Mercaptopurine in Pediatric Patients with Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.

Lee Y, Jang E, Yoon H, Yee J, Gwak H Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455413 PMC: 9027773. DOI: 10.3390/ph15040416.

Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias.

Jerves T, Blau N, Ferreira C Mol Genet Metab. 2022; 136(2):118-124.

PMID: 35422340 PMC: 9189061. DOI: 10.1016/j.ymgme.2022.03.011.

and Polymorphisms and Their Relation to Mercaptopurine-Related Myelotoxicity in Childhood Leukemia in Thailand.

Boonyawat B, Monsereenusorn C, Photia A, Lertvivatpong N, Kaewchaivijit V, Jindatanmanusan P Appl Clin Genet. 2021; 14:341-351.

PMID: 34349542 PMC: 8326781. DOI: 10.2147/TACG.S318912.

References

McLeod H, Lin J, Scott E, Pui C, Evans W . Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther. 1994; 55(1):15-20. DOI: 10.1038/clpt.1994.4. View

Morgan E, Honig G, Nelson D . Acute lymphocytic leukemia in a child with congenital xanthine oxidase deficiency: implications for therapy. Am J Pediatr Hematol Oncol. 1981; 3(4):439-41. View

Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I . Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia. 2008; 23(5):971-4. DOI: 10.1038/leu.2008.317. View

Bowne S, Liu Q, Sullivan L, Zhu J, Spellicy C, Bowes Rickman C . Why do mutations in the ubiquitously expressed housekeeping gene IMPDH1 cause retina-specific photoreceptor degeneration?. Invest Ophthalmol Vis Sci. 2006; 47(9):3754-65. PMC: 2581456. DOI: 10.1167/iovs.06-0207. View

Pieters R, Huismans D, Loonen A, Peters G, Hahlen K, van der Does-van den Berg A . Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukemia: relation with immunophenotype, in vitro drug resistance and clinical prognosis. Int J Cancer. 1992; 51(2):213-7. DOI: 10.1002/ijc.2910510208. View

Haglund S, Taipalensuu J, Peterson C, Almer S . IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol. 2007; 65(1):69-77. PMC: 2291267. DOI: 10.1111/j.1365-2125.2007.02985.x. View

Schmidt L, Dalhoff K . Food-drug interactions. Drugs. 2002; 62(10):1481-502. DOI: 10.2165/00003495-200262100-00005. View

Minoshima S, Wang Y, Ichida K, Nishino T, Shimizu N . Mapping of the gene for human xanthine dehydrogenase (oxidase) (XDH) to band p23 of chromosome 2. Cytogenet Cell Genet. 1995; 68(1-2):52-3. DOI: 10.1159/000133887. View

Adachi M, Reid G, Schuetz J . Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv Drug Deliv Rev. 2002; 54(10):1333-42. DOI: 10.1016/s0169-409x(02)00166-7. View

10.

Loennechen T, Utsi E, Hartz I, Lysaa R, Kildalsen H, Aarbakke J . Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway. Clin Pharmacol Ther. 2001; 70(2):183-8. DOI: 10.1067/mcp.2001.117445. View

11.

Stocco G, Cheok M, Crews K, Dervieux T, French D, Pei D . Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2008; 85(2):164-72. PMC: 2762405. DOI: 10.1038/clpt.2008.154. View

12.

Hawwa A, Millership J, Collier P, Vandenbroeck K, McCarthy A, Dempsey S . Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol. 2008; 66(4):517-28. PMC: 2561120. DOI: 10.1111/j.1365-2125.2008.03248.x. View

13.

McLeod H, Krynetski E, Relling M, Evans W . Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 2000; 14(4):567-72. DOI: 10.1038/sj.leu.2401723. View

14.

Sumi S, Marinaki A, Arenas M, Fairbanks L, Rees D, Thein S . Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002; 111(4-5):360-7. DOI: 10.1007/s00439-002-0798-z. View

15.

Relling M, Hancock M, Rivera G, Sandlund J, Ribeiro R, Krynetski E . Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999; 91(23):2001-8. DOI: 10.1093/jnci/91.23.2001. View

16.

Hedeland R, Hvidt K, Nersting J, Rosthoj S, Dalhoff K, Lausen B . DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2009; 66(3):485-91. DOI: 10.1007/s00280-009-1184-5. View

17.

Allorge D, Hamdan R, Broly F, Libersa C, Colombel J . ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut. 2005; 54(4):565. PMC: 1774451. DOI: 10.1136/gut.2004.055947. View

18.

Roberts R, Gearry R, Barclay M, Kennedy M . IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J. 2006; 7(5):312-7. DOI: 10.1038/sj.tpj.6500421. View

19.

Ogino S, Wilson R . Genotype and haplotype distributions of MTHFR677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis. J Hum Genet. 2003; 48(1):1-7. DOI: 10.1007/s100380300000. View

20.

Ban H, Andoh A, Imaeda H, Kobori A, Bamba S, Tsujikawa T . The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2010; 45(10):1014-21. DOI: 10.1007/s00535-010-0248-y. View